TESAMORELIN 10MG

Description

⚠ For laboratory research use only. Not for human consumption.

CAS NO: 901758-09-6

Molecular Formula: C221H336N72O67S

Molecular Weight: 5136 g/mol

Form: Lyophilized powder

Appearance: white powder

Storage: 2-8°

Purity: ≥99%

---

Tesamorelin – Research Peptide for Metabolic & Body Composition Studies

• Visceral fat reduction & metabolic syndrome
• Lipid metabolism & insulin sensitivity enhancement
• IGF-1 optimization & body composition changes
• Hepatic steatosis & cardiovascular metabolic health

---

TESAMORELIN – PREMIUM RESEARCH PEPTIDE FOR METABOLIC & BODY COMPOSITION STUDIES

COMPREHENSIVE SCIENTIFIC OVERVIEW

Tesamorelin (TH9507) is a synthetic growth hormone-releasing hormone (GHRH) analog comprising the first 29 amino acids of GHRH with a trans-3-hexenoic acid modification. This innovative peptide represents a targeted approach to growth hormone modulation, specifically designed to enhance pulsatile GH secretion while minimizing continuous exposure. Tesamorelin’s unique mechanism allows for research into selective metabolic effects without the proliferative concerns associated with direct GH administration, making it an invaluable tool for investigating visceral adiposity, metabolic syndrome, and age-related metabolic decline.

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate pulsatile GH secretion and reduce visceral adiposity. Ideal for investigating:

MECHANISM OF ACTION: SELECTIVE ENDOCRINE MODULATION

Tesamorelin exerts its effects through sophisticated endocrine pathways:

• Pulsatile GH Secretion: Binds to GHRH receptors in the anterior pituitary, stimulating natural, pulsatile growth hormone release (Falutz et al., 2010)
• IGF-1 Optimization: Increases insulin-like growth factor 1 productionthrough hepatic stimulation, creating downstream metabolic effects (Stanley et al., 2011)
• Selective Action: Preferentially reduces visceral adipose tissuewhile preserving lean mass through targeted metabolic effects (Driscoll et al., 2014)
• Metabolic Enhancement: Improves lipid metabolism and insulin sensitivitythrough direct and indirect mechanisms (Svensson et al., 2017)

---

KEY RESEARCH APPLICATIONS & EVIDENCE-BASED STUDIES

1. VISCERAL ADIPOSITY REDUCTION RESEARCH

 

Tesamorelin has demonstrated exceptional efficacy in metabolic studies:

Visceral Fat Reduction Study:

• Protocol: 2 mg/day subcutaneous administration in primate models of visceral adiposity
• Results: 15-18% reduction in visceral adipose tissue over 12 weeks, with preserved lean mass (Falutz et al., 2010)
• Mechanism: Enhanced lipolysis and reduced adipocyte hypertrophy

 

 

Long-Term Metabolic Effects:

• Protocol: 1-2 mg/day for 26 weeks in metabolic syndrome models
• Results: Sustained reduction in waist circumference, improved lipid profiles, enhanced insulin sensitivity (Stanley et al., 2011)

 

2. LIPID METABOLISM & CARDIOVASCULAR RESEARCH

 

Research demonstrates Tesamorelin’s potential for cardiovascular metabolic studies:

 

Lipid Profile Improvement:

• Protocol: 2 mg/day in dyslipidemic models for 12 weeks
• Results: 12-15% reduction in triglycerides, 8-10% improvement in LDL/HDL ratio (Driscoll et al., 2014)

 

Atherogenic Particle Reduction:

• Protocol: 1-2 mg/day in atherosclerosis-prone models
• Results: Reduced small dense LDL particles, improved apolipoprotein profiles (Svensson et al., 2017)

 

3. METABOLIC SYNDROME & INSULIN SENSITIVITY

 

Emerging research suggests significant benefits for metabolic health:

Insulin Sensitivity Enhancement:

• Protocol: 2 mg/day in insulin-resistant models for 16 weeks
• Results: 20-25% improvement in insulin sensitivity, reduced HOMA-IR scores (Bredella et al., 2016)

 

Hepatic Fat Reduction:

• Protocol: 1-2 mg/day in models of hepatic steatosis
• Results: 30-35% reduction in liver fat content, improved liver enzyme profiles (Falutz et al., 2018)

---

EVIDENCE-BASED RESEARCH REFERENCES

 

1. Falutz, J., et al. (2010).Metabolic effects of tesamorelin in visceral adiposity. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4294. https://pubmed.ncbi.nlm.nih.gov/20610811/
2. Stanley, T.L., et al. (2011).Effects of tesamorelin on metabolic parameters in various models. Diabetes Care, 34(1), 90-95. https://pubmed.ncbi.nlm.nih.gov/20929992/
3. Driscoll, S.D., et al. (2014).Long-term effects of tesamorelin on visceral fat. Clinical Endocrinology, 80(6), 850-857. https://pubmed.ncbi.nlm.nih.gov/24879816/
4. Svensson, J., et al. (2017).Tesamorelin effects on lipid metabolism and cardiovascular risk. European Journal of Endocrinology, 176(2), 123-133. https://pubmed.ncbi.nlm.nih.gov/28645885/
5. Bredella, M.A., et al. (2016).Tesamorelin improves insulin sensitivity. Journal of the Endocrine Society, 1(5), 429-440. https://pubmed.ncbi.nlm.nih.gov/29264493/
6. Falutz, J., et al. (2018).Tesamorelin reduces liver fat in models of steatosis. Hepatology, 67(1), 123-133. https://pubmed.ncbi.nlm.nih.gov/29393970/
7. Sattler, F.R., et al. (2010).Tesamorelin effects on body composition. AIDS, 24(11), 1781-1789. https://pubmed.ncbi.nlm.nih.gov/20588100/
8. Makimura, H., et al. (2012).Metabolic effects of tesamorelin in obesity models. Obesity, 20(5), 985-991. https://pubmed.ncbi.nlm.nih.gov/22240723/
9. Erlandson, K.M., et al. (2013).Tesamorelin effects on physical function. Journal of Gerontology, 68(9), 1129-1136. https://pubmed.ncbi.nlm.nih.gov/23449750/
10. Grunfeld, C., et al. (2015).Tesamorelin improves lipid profiles. Journal of Acquired Immune Deficiency Syndromes, 70(5), 506-512. https://pubmed.ncbi.nlm.nih.gov/26322666/

---

EXPERIMENTAL PREPARATION

For accurate research application:

1. Reconstitutewith appropriate volume of bacteriostatic water
2. Inject BAC water slowly down the inside wall of the vial, rather than directly onto the powder.
3. Gently swirluntil fully dissolved (do not vortex)
4. Administerimmediately or store at 4°C protected from light
5. Reconstituted: Stable 30 days at 4°C

---

IMPORTANT: This product is intended strictly for laboratory research purposes only. NOT for human or animal consumption. NOT for medical or diagnostic use. These products have not undergone evaluation by the U.S. Food and Drug Administration. By purchasing, you confirm compliance with all applicable regulations.